Evidence map›Paper›PMID 33932502›Full record

Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2021

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).

S Bellone, D M Roque, E R Siegel, N Buza, P Hui, E Bonazzoli, A Guglielmi, L Zammataro, N Nagarkatti, S Zaidi and 23 more

Abstract readClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Review
  9. Epigenetic regulation in gynecological cancers: a paradigm shift in immunotherapy strategies.Journal of experimental & clinical cancer research : CR · 2025
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Cancers · 2023
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

S BelloneSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
D M RoqueGreenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, USA.
E R SiegelDepartment of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, USA.
N BuzaSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
P HuiSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
E BonazzoliSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
A GuglielmiSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
L ZammataroSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
N NagarkattiSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
S ZaidiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA.
J LeeDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul, South Korea.
D-A SilasiDivision of Gynecologic Oncology, Mercy Clinic, St. Louis, USA.
G S HuangSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
V AndikyanSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
S DamastSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
M ClarkSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
M AzodiSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
P E SchwartzSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
J Tymon-RosarioSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
J HaroldSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
D MauricioSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
B ZeybekSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
G MenderesSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
G AltwergerSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
E RatnerSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
L B AlexandrovDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, USA.
A IwasakiSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
Y KongSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
E SongSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA.
W DongLaboratory of Human Genetics and Genomics, The Rockefeller University, New York, USA.
J ElvinCancer Genomics Research, Foundation Medicine, Cambridge, USA.
J ChoiDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul, South Korea.
A D SantinSmilow Comprehensive Cancer Center, Yale University School of Medicine, New Haven, USA. Electronic address: alessandro.santin@yale.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0M
Integrated genomic analysis of racial disparities in endometrial cancerU01CA176067 · NCI · YALE UNIVERSITY · PI SANTIN, ALESSANDRO D · 2014 to 2018
$1.7M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016359NCI NIH HHS U01 CA176067
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Endometrial NeoplasmsMicrosatellite InstabilityAntibodies, Monoclonal, HumanizedDNA Mismatch RepairFemaleHumansMicrosatellite RepeatsNeoplasm Recurrence, LocalAntibodies, Monoclonal, Humanizedpembrolizumab

Identifiers

PMID33932502
PMCPMC9465821

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.